GreenStar Biosciences (CSE:GSTR, OTC Pink:GTSIF) has launched their campaign on the Investing News Network’s life science channel.

GreenStar Biosciences (CSE:GSTR, OTC Pink:GTSIF) is a company focused on growth-oriented technologies with its core interest in transformational medicines and wellness. In particular, the company is targeting the psychedelic market in large part thanks to acquisitions and development of assets, products and technologies.


Within the psychedelics space, GreenStar Biosciences stands out from its competitors because it has physicians as part of its management team and four provisional patents filed for medicines that the company believes will have true efficacy in treating certain conditions.

Additionally, GreenStar Biosciences is forming a scientific advisory board that will focus largely on the psychedelics space because it is committed to the product basis and the types of medicine the company is developing.

GreenStar Biosciences’ company highlights include the following:

  • Is focused primarily in the US market for head trauma
  • Currently targeting the psychedelics market through its acquisition of Eleusian Biosciences
  • Therapeutic areas the company is focused on include  brain trauma and posttraumatic stress disorder (PTSD) associated with head trauma
  • Through the acquisition, GreenStar Biosciences acquired provisional patents to treat PTSD or mTBI with PTSD
  • A third provisional patent was also acquired for methods and compositions for treating mTBI PTSD alone with 3,4 MDMA plus NAC
  • Its fourth patent pending is a medical device for delivery of medicines to the olfactory bulb and GreenStar is currently searching for a device development partner.
  • Eleusian is collaborating with a multidisciplinary team of scientists and physicians from the University of Miami to develop therapeutics to treat mTBI  with PTSD or PTSD alone based on the combination of psilocybin and NAC
  • Through its subsidiary Cowlitz County Cannabis Cultivation Inc., GreenStar Biosciences owns certain assets including the property leases and intellectual property of Cowlitz
  • Cowlitz is one of the top 5 Tier 2 processors in Washington state and has its products  broadly available at dispensaries across the state

Click here to connect with GreenStar Biosciences (CSE:GSTR, OTC Pink:GTSIF) and to request an investor presentation.

  Life Science and Healthcare Investing in 2020 report cover

Coronavirus:An Overview for Investors

 
COVID-19 continues to impact world markets. Get INN’s overview of coronavirus investing.
 

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less